The Hydropathy Index of the HCDR3 Region of the B-Cell Receptor Identifies Two Subgroups of IGHV-Mutated Chronic Lymphocytic Leukemia Patients With Distinct Outcome

Arancha Rodríguez-Caballero1,2,3*, Blanca Fuentes Herrero1,2,3, Guillermo Oliva Ariza1,2,3, Ignacio Criado1,2,3, Miguel Alcoceba2,3,4, Carlos Prieto5, María Pérez Caro6, Andrés C. García-Montero1,2,3, Marcos González Díaz2,3,4, Francesco Forconi7, Ana Bela Sarmento-Ribeiro8,9, Julia Almeida1,2,3† and Alberto Orfao1,2,3*†

1 Translational and Clinical Research Program, Cancer Research Center Institute of Cancer Molecular and Cellular Biology (IBMCC), University of Salamanca-The Spanish National Research Council (USAL-CSIC), Department of Medicine and Cytometry Service, Nucleus Research Support Platform from University of Salamanca (NUCLEUS), University of Salamanca, Salamanca, Spain, 2 CIBERONC Program of Liquid Biopsy, Hematologic Tumors, Centro de Investigación Biomédica en Red de Cáncer CB16/12/00400 and CB16/12/00233 (CIBERONC), Madrid, Spain, 3 Molecular and Cellular Biology of Hematologic Tumors, Biomedical Research Institute of Salamanca (IBSAL), Salamanca, Spain, 4 Department of Hematology, University Hospital of Salamanca’s Biomedical Research Institute of Salamanca (HUS/IBSAL), Salamanca, Spain, 5 Bioinformatics Service, Nucleus Research Support Platform from University of Salamanca (NUCLEUS), University of Salamanca, Salamanca, Spain, 6 Spanish National DNA Bank Carlos III, University of Salamanca, Salamanca, Spain, 7 Haematology Oncology Group, School of Cancer Sciences, Cancer Research UK Centre and National Institute for Health Research Experimental Cancer Medicine, University of Southampton, Faculty of Medicine, Southampton, United Kingdom, 8 Faculty of Medicine, University of Coimbra (FMUC), Coimbra, Portugal, 9 Centro Hospitalar e Universitário de Coimbra (CHUC), Coimbra, Portugal

The HCDR3 sequences of the B-cell receptor (BCR) undergo constraints in length, amino acid use, and charge during maturation of B-cell precursors and after antigen encounter, leading to BCR and antibodies with high affinity to specific antigens. Chronic lymphocytic leukemia consists of an expansion of B-cells with a mixed immature and "antigen-experienced" phenotype, with either a mutated (M-CLL) or unmutated (U-CLL) tumor BCR, associated with distinct patient outcomes. Here, we investigated the hydropathy index of the BCR of 138 CLL patients and its association with the IGHV mutational status and patient outcome. Overall, two clearly distinct subgroups of M-CLL patients emerged, based on a neutral (mean hydropathy index of -0.1) vs. negatively charged HCDR3 sequences. Compared to M-CLL with neutral HCDR3 sequences, M-CLL with negatively charged HCDR3 sequences showed predominance of men, more advanced stages of the disease, and a greater frequency of genetic alterations—e.g., del(17p)—together with a higher rate of disease progression and shorter time to therapy (TTT), independently of other
prognostic factors. Our data suggest that the hydropathy index of the HCDR3 sequences of CLL cells allows the identification of a subgroup of M-CLL with intermediate prognostic features between U-CLL and the more favorable subgroup of M-CLL with a negatively charged BCR.

Keywords: hydropathy index, neutral HCDR3, negatively charged HCDR3, mutated CLL (M-CLL), disease progression

INTRODUCTION

Chronic lymphocytic leukemia (CLL) is the most prevalent leukemia in adults in the Western world, which is characterized by an expansion of mature-appearing CD5⁺CD20lo B-cells showing an antigen-experienced CD27⁺, IgM⁺, and/or IgD⁺ unswitched phenotype, in association with either an unmutated (U-CLL) or mutated (M-CLL) B-cell receptor (BCR) (1). At diagnosis, most CLL patients show stable disease with a variable number of tumor B-cells in blood (always >5,000 cells/μl) and bone marrow (BM), in the absence of organomegalies, and they do not require active therapy (2). Despite this, a significant fraction of patients shows more advanced disease already at diagnosis or they experience disease progression during follow-up, which translates into the need for active cytotoxic therapy (3).

In the last decades, the mutational status of the immunoglobulin (IG) heavy-chain variable (IGHV) genes that code for the BCR, together with disease stage and tumor cytogenetics, has emerged among other variables, as relevant prognostic factors in CLL (4). Thus, U-CLL patients show a significantly poorer outcome compared to M-CLL (4). Thereby, analysis of the IGHV status is currently part of the core variables investigated in the diagnostic workup of this disease (3, 5). Despite this, M-CLL patients have a heterogeneous outcome (6, 7).

From a pathogenic point of view, U-CLL cells resemble “pre-germinal center” (pre-GC) B-cells, whereas M-CLL cells mimic “post-GC” B-lymphocytes (8, 9). However, tumor cells from both CLL groups typically display a mixed immature (CD5⁺ CD23⁻) and “antigen-experienced” (CD27⁺) B-cell phenotype (10), suggesting they might represent the leukemic counterpart of B-lymphocytes that might have undergone BCR stimulation in the GC (M-CLL) vs. peripheral tissues, following selection of B-cell precursors in BM (U-CLL). In line with this hypothesis, the IGHV1-69/IGHJ6 genes which show highly similar junctional regions to those of normal peripheral blood (PB) CD5⁺ GC B-cells are more frequently represented among U-CLL, supporting a close relationship between U-CLL cells and the B-cells responsible for the natural antibody repertoire (11). This potential relationship is further supported by the fact that most normal CD5⁺ B-cells isolated from blood correspond to immature and (early) naïve B-cells that express unmutated VH gene regions (12). In turn, B-cell activation via T-cell-dependent antigens leads to the expansion of hypermutated germinal center (GC)-derived B-cells (13), suggesting that M-CLL might be associated with the “classical unswitched memory B-cell” compartment, despite that some M-CLL also show BCR features that overlap with those of natural antibodies (14).

Another important biological feature of CLL is the usage of a biased IGHV-D-J repertoire (the so-called “stereotyped” BCR) (9) in around one-third of cases, particularly in U-CLL patients, with important pathogenic and prognostic implications (15, 16). In contrast to U-CLL, the higher load of somatic mutations in the BCR of M-CLL cases makes recognition of common amino acid (aa) patterns in the HCDR3 region more difficult (17). However, other HCDR3 characteristics, such as its overall charge and hydropathy index, might also contribute to better understand the ontogeny of tumor B-cells in CLL, the affinity and specificity profile of their BCR, and its relationship with antigen-driven B-cell responses, even at earlier stages of B-cell maturation (18). In fact, the HCDR3 sequence of the BCR undergoes constraints in length, amino acid use, and charge along the B-cell development and maturation (19). Consequently, the BCR repertoire of early B-cell progenitors is first focused into what appears to be a preferred range for functional antigen recognition by mature B-cells, and subsequently modified after antigen recognition, in order to generate high-affinity antigen-specific antibodies and memory B-cells (19, 20). Interestingly, receptor prototypes based on HCDR3 charge and its association with certain V gene characteristics have been defined in CLL cells with the possibility that such receptor restrictions could reflect selections of the BCR repertoire that have occurred among both antigen-experienced and naïve B cells (21). Despite this, the hydropathy features of HCDR3 and its association with the IGHV mutational status and other clinical and biological features of the disease have not been systematically explored in large series of CLL and related with patient outcome.

Here we investigated the hydropathy index of the BCR of tumor cells from 138 CLL patients, and its potential association with other features of the disease, including the BCR mutational status and patient outcome.

MATERIALS AND METHODS

Patients and Samples

A total of 138 untreated CLL patients—81 males and 57 females; median age (range) at diagnosis of 63 years (y) (33–84 y)—diagnosed at the University Hospital of Salamanca (Salamanca, Spain) were studied. Most cases (95/138) had Binet stage A CLL, and 43 had more advanced CLL (Binet B, 22; and Binet C, 21 patients). Median follow-up at the time of study closure was 8 y; at that time, 65 patients (47%) had progressed and required therapy and 24 (17%) had died (Table 1). In every patient, genomic DNA (gDNA) from purified CLL B-cells was obtained for molecular investigations. The study was approved by the local institutional Ethics Committee (approval code: CEIC-P14705/2017). All patients gave their written informed consent to participate to the study in agreement with the Declaration of Helsinki.
TABLE 1 | Clinical and biological features of CLL patients classified according to the HCDR3 hydropathy index.

| Patient features                          | CLL with neutral HCDR3 (N = 65) | CLL with negatively charged HCDR3 (N = 73) | p-value |
|-------------------------------------------|---------------------------------|------------------------------------------|---------|
| Age at diagnosis (years)                  | 63 (33–84)                      | 65 (35–84)                               | 0.47    |
| Men/women*                               | 47/18 (72%/28%)                 | 34/39 (47%/53%)                          | 0.002   |
| Binet stage*                              |                                 |                                          |         |
| A                                         | 37 (57%)                        | 58 (79%)                                 | 0.006   |
| B                                         | 12 (18%)                        | 10 (14%)                                 |         |
| C                                         | 16 (25%)                        | 5 (7%)                                   |         |
| Rai stage*                                |                                 |                                          |         |
| 0                                         | 30/65 (46%)                     | 54/73 (74%)                              | 0.01    |
| I                                         | 6/65 (9%)                       | 7/73 (10%)                               |         |
| II                                        | 9/65 (14%)                      | 5/73 (7%)                                |         |
| III                                       | 6/65 (9%)                       | 2/73 (3%)                                |         |
| IV                                        | 14/65 (21%)                     | 5/73 (7%)                                |         |
| Hemoglobin (g/L)                          | 140 (70–180)                    | 130 (90–170)                             | 0.94    |
| Anemia (<100 g of hemoglobin/L)*          | 7.65 (11%)                      | 3.71 (4%)                                | 0.13    |
| N. of platelets (<100 × 10^9/L)*          | 154 (15–429)                    | 157 (48–448)                             | 0.11    |
| N. of PB leukocytes (<10^9/L)             | 36 (6–352)                      | 34 (8–578)                               | 0.40    |
| Thrombocytopenia (<100 × 10^9 platelets/L)* | 3.2 (0.8–7.4)           | 2.8 (0.5–14)                             | 0.68    |
| N. of PB total T-cells (<10^9/L)          | 1.6 (0.5–4.4)                   | 1.7 (0.3–5.9)                            | 0.64    |
| N. of PB CD8+ T-cells (<10^9/L)           | 0.8 (0.1–3.5)                   | 0.9 (0.1–8)                              | 0.60    |
| N. of PB CD4+ T-cells (<10^9/L)           | 0.6 (0.01–2)                    | 0.4 (0.01–2.9)                           | 0.24    |
| N. of PB monocytes (<10^9/L)              | 6.4 (0.9–20.7)                  | 6.1 (0.2–19.4)                           | 0.50    |
| N. of PB neutrophils (<10^9/L)            | 0.07 (0.005–0.5)                | 0.06 (0.015–0.6)                         | 1.0     |
| N. of PB eosinophils (<10^9/L)            | 0.2 (0.02–1.7)                  | 0.2 (0.01–1.2)                           | 0.16    |
| N. of PB basophils (<10^9/L)              | 0.6 (0.04–2.1)                  | 0.5 (0.04–3.2)                           | 0.60    |
| N. of PB monocytes (<10^9/L)              | 4.1 (1.4–334.8)                 | 20.9 (0.8–278.9)                         | 0.11    |
| Hemoglobin (g/L)                          | 140 (70–180)                    | 130 (90–170)                             | 0.94    |
| Anemia (<100 g of hemoglobin/L)*          | 7.65 (11%)                      | 3.71 (4%)                                | 0.13    |
| N. of platelets (<100 × 10^9/L)*          | 154 (15–429)                    | 157 (48–448)                             | 0.11    |
| N. of PB leukocytes (<10^9/L)             | 36 (6–352)                      | 34 (8–578)                               | 0.40    |
| Thrombocytopenia (<100 × 10^9 platelets/L)* | 3.2 (0.8–7.4)           | 2.8 (0.5–14)                             | 0.68    |
| N. of PB total T-cells (<10^9/L)          | 1.6 (0.5–4.4)                   | 1.7 (0.3–5.9)                            | 0.64    |
| N. of PB CD8+ T-cells (<10^9/L)           | 0.8 (0.1–3.5)                   | 0.9 (0.1–8)                              | 0.60    |
| N. of PB CD4+ T-cells (<10^9/L)           | 0.6 (0.01–2)                    | 0.4 (0.01–2.9)                           | 0.24    |
| N. of PB monocytes (<10^9/L)              | 6.4 (0.9–20.7)                  | 6.1 (0.2–19.4)                           | 0.50    |
| N. of PB neutrophils (<10^9/L)            | 0.07 (0.005–0.5)                | 0.06 (0.015–0.6)                         | 1.0     |
| N. of PB eosinophils (<10^9/L)            | 0.2 (0.02–1.7)                  | 0.2 (0.01–1.2)                           | 0.16    |
| N. of PB basophils (<10^9/L)              | 0.6 (0.04–2.1)                  | 0.5 (0.04–3.2)                           | 0.60    |
| N. of PB monocytes (<10^9/L)              | 4.1 (1.4–334.8)                 | 20.9 (0.8–278.9)                         | 0.11    |
| % IGHV homology with germ line counterpart | 99% (86%–100%)                 | 96% (85%–100%)                           | 0.04    |
| HCDR3 length of CLL clone (N. of aa)      | 19 (8–28)                      | 16 (7–25)                                | 0.004   |
| Cyogenetically altered CLL patients*      | 55/65 (85%)                     | 59/72 (82%)                              | 0.43    |
| Del(13q14)/D13S25*                        | 22/65 (34%)                     | 32/72 (44%)                              | 0.14    |
| Trisomy 12*                               | 16/65 (25%)                     | 11/72 (15%)                              | 0.12    |
| Del(11q)/ATM*                             | 6/65 (9%)                       | 6/72 (10%)                               | 0.54    |
| Del(17p)*                                 | 3/62 (5%)                       | 1/69 (1%)                                | 0.29    |
| N. of cyogenetically altered cells (<10^9/L) | 19 (0–233)                  | 11 (0–185)                               | 0.19    |
| Disease progression*                      | 39/65 (60%)                     | 26/73 (36%)                              | 0.003   |
| TTT < 2 years*                            | 20/65 (31%)                     | 8/73 (11%)                               | 0.004   |
| Deaths*                                   | 11/65 (17%)                     | 13/73 (18%)                              | 0.54    |

Results expressed as median (range) or as # number of cases (percentage).

aa, amino acids; CLL, chronic lymphocytic leukemia; M, mutated IGHV; N, number; PB, peripheral blood; TTT, time to therapy; U, unmutated IGHV.

IGHV-D-J Gene Rearrangement Studies

Analysis of the tumor IGHV-D-J gene rearrangements was performed by polymerase chain reaction (PCR) of gDNA from fluorescence-activated cell sorting (FACS)-purified tumor CLL cells according to the ERIC protocols (22), as previously described in detail (23, 24). For IGHV sequencing, PCR amplicons were subjected to direct sequencing on both strands. Sequence data were analyzed using the IMGT databases and the IMGT/V-QUEST tool (http://www.imgt.org). Classification into the U-CLL vs. M-CLL categories was based on the well-established 98% cutoff identity to the germline sequence (U-CLL: 98%–100%; M-CLL: <98%) (21).

Calculation of the Hydropathy Index of HCDR3 Protein Sequences

To determine the hydropathy index—grand average of hydropathy (GRAVY) score—of the HCDR3 protein sequences, the ProtScale Tool from the ExPASy Bioinformatics Resource Portal (https://web.expasy.org/protscale/) and the amino acid (aa) scale values, as defined by Kyte and Doolittle (25), were used (Supplementary Figures 1A, B). The Gravy score (GS) was calculated for each HCDR3 sequence by summing up the hydropathy index value of each amino acid residue in the individual HCDR3 sequences and dividing the sum obtained by the number of amino acids in each specific sequence (23) (Supplementary Table 1 and Supplementary Figures 1B, C). Since the HCDR3 hydropathy index in humans follows a Gaussian distribution centered in the neutral/hydrophilic range (average charge: -0.5) (19), each HCDR3 sequence was classified into the neutral HCDR3 (GS ≥ -0.5) or negatively charged HCDR3 (GS < -0.5) categories.

Cytogenetic Analyses

The most common cytogenetic alterations associated with CLL—i.e., del(13q14), trisomy 12, del(11q) (ATM), and del(17p) (TP53)—were investigated by iFISH on FACS-purified (single) tumor B cells (≥95% purity), as described elsewhere (23, 26).
Statistical Methods
For all continuous variables, median (range) values were calculated, while for categorical variables, frequencies were used. Either the Mann–Whitney U test or the chi-squared test was used to establish the statistical significance of differences observed between two groups, for continuous and categorical variables, respectively. To avoid associations occurring by chance due to multiple simultaneous comparisons, p-values were Bonferroni-adjusted for comparisons of continuous variables among three study groups. Time from diagnosis to (first) therapy (TTT) curves were built using the Kaplan–Meier method and compared by the (one-sided) log-rank test. Receiver operating characteristic (ROC) curve analysis was performed to determine the cutoff values of continuous variables that best distinguish disease progression. Multivariate analysis using the Cox regression model was performed to identify those variables independently associated with a greater/lower risk of disease progression (in terms of TTT) among M-CLL patients. All statistical analyses were performed with SPSS 25.0 (SPSS-IBM, Armonk, NY), and statistical significance was set at p-values ≤ 0.05, unless Bonferroni-adjusted p-values were applied (≤ 0.013).

RESULTS
HCDR3 Hydropathy Index in CLL and Its Relationship With Other Disease Features
Overall, a similar frequency of CLL patients with neutral (GS ≥ -0.5) and negatively charged (GS < -0.5) HCDR3 amino acid sequences was observed in our cohort: 65/138 (47%) vs. 73/138 (53%) CLL patients (p = 0.46), respectively (Figure 1). CLL patients with neutral or negatively charged HCDR3 showed no significant (p > 0.05) differences in age distribution, hemoglobin levels, leukocyte or platelet counts, CLL cell counts in blood, and the overall tumor cell cytogenetic profiles (Table 1).

In contrast, CLL patients with neutral HCDR3 sequences showed a significant predominance of men vs. women (72% vs. 47%, p = 0.002), together with a lower percentage of Rai stage 0 (46% vs. 74%, p = 0.01) and Binet stage A cases (57% vs. 79%, p = 0.006), a higher proportion of cases with thrombocytopenia (21% of cases vs. 7%, p = 0.01), a lower proportion of M-CLL cases (46% vs. 66%, p = 0.02), and a lower median percentage of IGHV mutations (1% vs. 4%, p = 0.04) with longer HCDR3 sequences (median: 19 vs. 16 amino acids, p = 0.004) compared to CLL patients with negatively charged HCDR3 (Table 1). This CLL profile with neutral HCDR3 sequences translated into a significantly (p = 0.003) higher risk of disease progression (60% vs. 36%) and thereby also a higher percentage of cases that had required therapy at 2 y from diagnosis (31% vs. 11%, p = 0.004) (Table 1), and a significantly shortened TTT—median (95% confidence interval): 6 y (4–8 y) vs. not reached, p = 0.003 (Figure 2A). Of note, the prognostic impact of the HCDR3 hydropathy index was specifically restricted to M-CLL patients, while it did not show an impact on the already poorer outcome of U-CLL cases (Figure 2B).

HCDR3 Hydropathy Index in M-CLL vs. U-CLL and Its Association With Other Disease Features
Based on the above findings, we subdivided M-CLL patients into cases with neutral HCDR3 (mean GS of -0.1) and patients with negatively charged HCDR3 sequences (mean GS of -1.1) and

![Figure 1](https://www.frontiersin.org)
compared the features of these two subgroups of M-CLL vs. U-CLL cases (Table 2). Thus, Rai stage 0 (p = 0.007) predominated in the two M-CLL patient subgroups vs. U-CLL (Table 2). In contrast, greater median hemoglobin levels (150 vs. 130 g/L, p = 0.004) were found in M-CLL patients with a neutral HCDR3 (but not within those with a negatively charged HCDR3) vs. U-CLL. Overall, the number of PB leukocytes, total T cells, CD8+ T-cells, and tumor CLL cells, in blood, were all significantly increased in U-CLL compared with the two M-CLL patient groups, in the absence of significant differences between the later M-CLL groups (Table 2). Despite this, M-CLL with neutral HCDR3 sequences showed an intermediate frequency of cytogenetically

FIGURE 2  Time to therapy (TTT) survival curves of CLL patients distributed according to the hydropathy index of the HCDR3 aa sequence and the mutational status of their tumor cell BCR. Prognostic impact of the HCDR3 hydropathy index (A) and both the HCDR3 hydropathy index and the IGHV mutational status (B) on the outcome of CLL patients assessed by their survival from diagnosis to first therapy (TTT).
altered cases between U-CLL and M-CLL with negatively charged HCDR3 (80% vs. 92% and 74%, respectively) together with a significantly greater proportion of del(17p)<sup>1</sup> patients (11% vs. 0% and 2%, respectively; p = 0.02) (Table 2).

Regarding outcome, M-CLL with neutral HCDR3 sequences showed an intermediate rate of disease progression (37%) compared to both U-CLL patients (75%) (p < 0.001) and M-CLL with negatively charged HCDR3 sequences (19%), after a similar median follow-up (Table 2). This was associated with a significantly lower percentage of M-CLL cases with negatively charged HCDR3 sequences that required therapy during the first 2 years after diagnosis (2%) compared to U-CLL (37%, p < 0.001) and M-CLL with a neutral HCDR3 (17%, p = 0.03) (Table 2). This translated into significantly prolonged TTT among M-CLL with negatively charged HCDR3 sequences compared to both M-CLL patients with a neutral HCDR3 sequence and U-CLL patients—75th percentile TTT (95% confidence interval): not reached vs. 4.2 and 0.9 y, respectively; p < 0.001) (Figure 2B).

Based on the results above, we specifically investigated the prognostic impact of the hydropathy index of the HCDR3 sequence of the tumor cell BCR compared to other clinical and laboratory variables in patients with M-CLL. Among all variables analyzed, Binet stage (p < 0.001), the number of total T-cells (p < 0.001), CD4<sup>+</sup> T-cells (p = 0.002), CD8<sup>+</sup> T-cells (p = 0.001), basophils (p = 0.04), the size of the tumor B-cell clone in blood (p = 0.003), del(11q) and/or del(17p) (p = 0.04) and the number of cytogenetically altered CLL cells (p = 0.001) in addition to the hydropathy index of the HCDR3 sequences of the tumor B-cell clone (p < 0.001) all showed a prognostic impact in the univariate analysis (Table 3). Multivariate analysis confirmed the

### TABLE 2 | Clinical and biological features of CLL patients classified according to their IGHV mutational status and the HCDR3 hydropathy index.

| Patient features | U-CLL (N = 60) | M-CLL (N = 78) | p-value |
|------------------|---------------|---------------|---------|
| **Age at diagnosis (years)** | 64 (33–84) | 61 (38–81) | 63 (35–84) | 0.21 |
| **Men/women<sup>a</sup>** | 36/22 (63%/37%) | 20/10 (67%/33%) | 23/25 (48%/52%) | 0.16; 0.06<sup>b,c</sup> |
| **Binet stage<sup>d</sup>** | | | | |
| A | 37 (62%) | 21 (70%) | 37 (77%) | 0.14 |
| B | 14 (23%) | 2 (7%) | 6 (13%) | |
| C | 9 (15%) | 7 (23%) | 5 (10%) | |
| **Rai stage<sup>e</sup>** | | | | |
| 0 | 29/60 (48%) | 19/30 (63%) | 36/48 (75%) | 0.007; 0.02<sup>a</sup>; 0.04<sup>b</sup> |
| I | 6/60 (10%) | 4/30 (13%) | 3/48 (6%) | |
| II | 12/60 (20%) | 0/30 (0%) | 2/48 (4%) | |
| III | 6/60 (10%) | 0/30 (0%) | 2/48 (4%) | |
| IV | 7/60 (12%) | 7/30 (23%) | 5/48 (10%) | |
| **Hemoglobin (g/L)** | 149 (70–170) | 150 (100–180) | 130 (80–170) | 0.010; 0.004<sup>a</sup> |
| **Neutrophils** | 0.2 (0.01–1.4) | 0.4 (0.01–3.5) | 0.2 (0.05–3.7) | |
| **Lymphocytes** | 4 (0.5–14) | 2.7 (0.9–7.4) | 2.6 (0.6–9) | 0.006; 0.003<sup>b</sup> |
| **Platelets** | 55 (10–576) | 23 (6–245) | 8 (21–84) | 0.001; 0.010<sup>b</sup> |
| **CD4<sup>+</sup> T-cells** | 1.8 (0.6–6) | 1.5 (0.5–5.4) | 1.5 (0.3–4.3) | 0.04 |
| **CD8<sup>+</sup> T-cells** | 1.4 (0.1–8) | 0.7 (0.2–5) | 0.8 (0.1–5) | 0.007; 0.005<sup>b</sup> |
| **Monocytes** | 0.7 (0.01–3) | 0.5 (0.02–1.4) | 0.4 (0.01–2) | 0.12 |
| **Neutrophils** | 0.3 (0.9–21) | 0.3 (0.9–16) | 0.6 (0.2–12) | 0.47 |
| **B cells** | 7.3 (0.05–0.6) | 0.06 (0.02–0.5) | 0.06 (0.01–0.3) | 0.66 |
| **Eosinophils** | 0.7 (0.04–3) | 0.6 (0.05–1.5) | 0.4 (0.04–2.2) | 0.014 |
| **Tumor B-cell clone size in blood** | 47 (8.3–335) | 16 (1.4–238) | 17 (4.4–219) | 0.001; 0.011<sup>b</sup> |
| **% IGKV homology with germ line counterpart** | 99.5 (98.8–100) | 93.7 (86–98) | 93.3 (85–98) | <0.001; <0.001<sup>a</sup> |
| **HCDR3 length of CLL clone (N of aa)** | 21 (12–28) | 16 (8–24) | 16 (7–24) | <0.001; <0.001<sup>a</sup> |
| **Cytogenetically altered CLL patients<sup>b</sup>** | 55/60 (92%) | 24/30 (80%) | 35/47 (74%) | 0.05; 0.02<sup>c</sup> |
| **De17(13q)/D7S25**<sup>a</sup> | 25/60 (42%) | 11/30 (37%) | 18/47 (38%) | 0.88 |
| **Trisomy12<sup>a</sup>** | 17/60 (28%) | 3/30 (10%) | 7/47 (15%) | 0.04; 0.04<sup>c</sup> |
| **Del11q(11q)/ATM**<sup>a</sup> | 9/60 (15%) | 1/30 (3%) | 2/47 (4%) | 0.07; 0.06<sup>c</sup> |
| **Del17p<sup>a</sup>** | 7/60 (12%) | 3/30 (10%) | 1/48 (2%) | 0.02; 0.02<sup>c</sup> |
| **Number of cytogenetically altered cells (×10<sup>6</sup>)** | 28 (0–208) | 8.6 (6–233) | 6.3 (6–186) | 0.12 |
| **Tumor burden** | 45/60 (75%) | 11/30 (37%) | 9/48 (19%) | <0.001; <0.001<sup>a</sup> |
| **TTT < 2 years**<sup>a</sup> | 22/60 (37%) | 5/30 (17%) | 1/48 (2%) | <0.001; 0.04<sup>c</sup>; <0.001<sup>b</sup>; 0.03<sup>c</sup> |
| **Deaths**<sup>a</sup> | 16/60 (27%) | 2/30 (7%) | 6/48 (12%) | 0.03; 0.02<sup>a</sup> |

Results expressed as median (range) or as # number of cases (percentage).

<sup>a</sup>U-CLL vs. M-CLL with neutral HCDR3.

<sup>b</sup>U-CLL vs. M-CLL with negatively charged HCDR3.

<sup>c</sup>M-CLL with neutral HCDR3 vs. M-CLL with negatively charged HCDR3.

CLL, chronic lymphocytic leukemia; M, mutated IGKV; N, number; PB, peripheral blood; TTT, time to therapy; U, unmutated IGKV.
independent adverse prognostic impact of neutral HCDR3 sequence of BCR (hazard ratio (HR), 12; 95% confidence interval (CI), 1.8 to 81; \( p = 0.01 \)) together with an advanced Binet stage B/C (HR, 42.8; 95% CI, 1.7 to 1,073; \( p = 0.02 \)) (Table 3).

**Distinctive Molecular Features of the BCR of M-CLL With Neutral vs. Negatively Charged HCDR3 Sequences**

Interestingly, no significant differences were found between the two groups of M-CLL patients defined by having a neutral vs. negatively charged HCDR3, as regards the frequency of V(H) gene families used (Table 4). Despite this, both groups of M-CLL patients (with neutral and negatively charged HCDR3 sequences) more frequently used the VH3 gene at the expense of a lower frequency of VH1 gene usage compared to U-CLL patients—53% and 52% vs. 32%, (\( p = 0.05 \)) and 17% and 8% vs. 47%, (\( p < 0.001 \)), respectively (Table 4). In more detail, usage of the VH1-69 gene family was significantly associated with U-CLL—27% vs. 0% and 4%, \( p < 0.001 \)—while VH4-34 was more frequently used in the two groups of (neutral and negatively charged HCDR3) M-CLL patients vs. U-CLL—17% and 21% vs. 3%, \( p = 0.02 \), respectively. Interestingly, VH3-7 was significantly associated with M-CLL with neutral HCDR3 sequences (17%) while rarely found in U-CLL (2%) (\( p = 0.01 \)) (Table 3). Likewise, usage of the D(H)2 genes was more frequently observed in M-CLL with neutral HCDR3 sequences (43%) than in M-CLL with negatively charged HCDR3 (19%, \( p = 0.02 \)) and U-CLL (22%, \( p = 0.03 \)) patients (Table 4). Within the D(H)2 gene family, D(H)2-15 and D(H)2-21 were those family members more frequently expressed in M-CLL with neutral HCDR3 sequences vs. U-CLL (13% and 20% vs. 2% and 5%, respectively) (Table 4). In turn, U-CLL showed a higher frequency of D(H)3 than M-CLL patients (\( p = 0.001 \)), the D(H)3-3 gene family mostly accounting for these differences as it was found in 30% of U-CLL vs. 7% of M-CLL with neutral HCDR3 and 12% of M-CLL with negatively charged HCDR3 sequences (\( p = 0.01 \)) (Table 4).

Regarding J(H) gene usage, M-CLL with negatively charged HCDR3 sequences showed a significantly higher frequency of J(H)4 genes (60%) than both M-CLL with a neutral HCDR3 (23%) (\( p = 0.001 \)) and U-CLL (33%) (\( p = 0.004 \)) patients (Table 4). Likewise, a significantly lower percentage of M-CLL with negatively charged HCDR3 sequences showed J(H)6 gene usage (21%) compared to U-CLL (48%, \( p = 0.003 \)) (Table 4). Interestingly, the lower use of JH6 and DH2 genes in M-CLL with negatively charged HCDR3 sequences was associated with different charges of the specific HCDR3 amino acids comprised by these coding genes vs. U-CLL patients (\( p = 0.010 \) and \( p = 0.003 \), respectively) (Table 4). In contrast, the charge of the HCDR3 amino acids comprised by JH4 and DH3 genes did not show differences between U-CLL and both M-CLL groups (Table 4). It should be noted, however, that the HCDR3 fraction comprised by nucleotides distinct to those included in the above referred JH and DH gene sequences showed always a significantly lower charge in M-CLL patients with negatively charged sequences compared to M-CLL with neutral HCDR3 sequences (Table 4).

As expected, U-CLL had longer HCDR3 (median: 21 amino acids) than M-CLL (median: 16 amino acids) (\( p < 0.001 \)) (Table 2). However, since the length of the BCR HCDR3 sequences differs between B-cells from younger and older subjects (27), we grouped our patients into younger adults (≤65 y) and older (>65 y) patients. Interestingly, older M-CLL patients with a negatively charged HCDR3 showed shorter HCDR3 sequences (median: 15 amino acids) than M-CLL with neutral HCDR3 (median: 18 amino acids) (\( p = 0.013 \)) (Table 4). Furthermore, older M-CLL patients with neutral HCDR3 had similarly longer HCDR3 sequences (median: 18 amino acids) to those of U-CLL patients (median: 20 amino acids) (\( p = 0.47 \)) (Table 4). Finally, M-CLL with negatively charged HCDR3 sequences showed a significantly lower frequency of stereotyped IGHV sequences (10%) compared to U-CLL (28%) (\( p = 0.02 \)) (Table 4), with a similarly low incidence of stereotyped IGHV sequences corresponding to the more aggressive (#1, #2, #8) CLL subsets (Table 4).

**DISCUSSION**

B-cells are a key component of the adaptive immune system (28). Their function is typically triggered through BCR-mediated recognition of specific antigens (28). Specific binding of BCR to antigens is mostly mediated through unique HCDR3 (and also LCDR3) regions capable of identifying and attaching to complementary epitopes in the recognized antigen (28). For adequate binding to the antigen, electrostatic links with the BCR are required (29). Thereby, the HCDR3 charge plays a critical role in antigen binding to the BCR and recognition by B-cells (30). Importantly, during antigen-driven maturation, B-cells modify their HCDR3 sequences to enhance their affinity for specific antigen triggers (30). This includes acquisition of somatic mutations involving the HCDR3 region, which progressively confer more negatively charged amino acid sequences for higher affinity antigen binding by both the BCR and the future B-cell derived (higher-affinity) antibodies (31). In addition, due to its key role in antigen recognition, the interaction of the BCR with the BM microenvironment also plays a critical role at an earlier stage, during lymphopoesis, in selecting B-cell precursors that carry a functional BCR (31).

For decades now, studies have accumulated which support an important role for BCR-mediated expansion of tumor cells in CLL (32, 33) in the absence of a common genetic driver (6). Thus, CLL cells show biased usage of specific IGHV(DJ) gene families, with overrepresentation of some genes such as IGHV1-69, IGHV4-34, and IGHV3-21 (34). Of note, these genes are differentially distributed among the two major prognostic subgroups of CLL defined according to the mutational status of the BCR (U-CLL and M-CLL) (35). Accordingly, U-CLL cells have polyreactive BCRs that may respond to a wide spectrum of epitopes (36, 37), as typically required during selection of recently produced immature B-lymphocytes in BM (38), whereas M-CLL cells are more mature B-cells that have undergone somatic hypermutation, whose BCRs are (potentially) less responsive to external signals, while more
### TABLE 3 | Univariate and multivariate analyses of prognostic factors with an impact on disease progression in M-CLL (N = 78).

| Variables | N | Univariate analysis on disease progression | Multivariate analysis on disease progression |
|-----------|---|--------------------------------------------|---------------------------------------------|
|           |   | Median (95% CI) (y) | p-value | HR (95% CI) | p-value |
| Age at diagnosis | | | | | |
| ≤ 65 y | 50 | NR | 0.12 |
| > 65 y | 28 | NR | |
| Sex | | | | | |
| Men | 43 | NR | 0.88 |
| Women | 35 | NR | |
| Binet stage | | | | | |
| A | 58 | NR | |
| B/C | 20 | 8 (1.6–14.4) | <0.001 | 42.8 (1.7–1,073) | 0.02 |
| Anemia | | | | | |
| <100 g hemoglobin/L | 3 | 9.9 (5–15.9) | 0.27 |
| ≥100 g hemoglobin/L | 74 | NR | |
| Thrombocytopenia | | | | | |
| <100 platelets × 10^9/L | 12 | 9.9 | 0.08 |
| ≥100 platelets × 10^9/L | 65 | NR | |
| N. of PB leukocytes (×10^9/L) | | | | | |
| ≤51.4 | 57 | NR | 0.06 |
| >51.4 | 20 | NR | |
| N. of PB total T-cells (×10^9/L) | | | | | |
| ≤3.2 | 56 | NR | <0.001 |
| >3.2 | 21 | 6.2 (2.7–9.7) | |
| N. of PB CD4+ T-cells (×10^9/L) | | | | | |
| ≤2.1 | 60 | NR | 0.002 |
| >2.1 | 15 | 8.7 (4.1–13.2) | |
| N. of PB CD8+ T-cells (×10^9/L) | | | | | |
| ≤1.7 | 63 | NR | 0.001 |
| >1.7 | 12 | 6.1 (5.9–6.4) | |
| N. of PB monocytes (×10^9/L) | | | | | |
| ≤1.04 | 67 | NR | 0.27 |
| >1.04 | 7 | NR | |
| N. of PB neutrophils (×10^9/L) | | | | | |
| ≤11.4 | 73 | NR | 0.07 |
| >11.4 | 3 | 6.1 | |
| N. of PB basophils (×10^9/L) | | | | | |
| ≤0.13 | 51 | NR | 0.04 |
| >0.13 | 5 | 8.7 (1.4–16) | |
| N. of PB eosinophils (×10^9/L) | | | | | |
| ≤0.12 | 24 | NR | 0.08 |
| >0.12 | 50 | NR | |
| N. of PB NK cells (×10^9/L) | | | | | |
| ≤0.53 | 39 | NR | 0.31 |
| >0.53 | 32 | NR | |
| Tumor B-cell clone size in blood (×10^9/L) | | | | | |
| ≤37.7 | 53 | NR | 0.003 |
| >37.7 | 23 | 9.93 | |
| HCDR3 hydropathy index | | | | | |
| Neutral | 30 | 4.2 (75th percentile: NR) | <0.001 | 12 (1.8–81) | 0.01 |
| Negatively charged | 48 | NR (75th percentile: NR) | |
| % IGHV homology | | | | | |
| ≤96 | 65 | NR | 0.56 |
| >96 | 13 | NR | |
| HCDR3 length of CLL clone | | | | | |
| ≤21 aa | 73 | NR | |
| >21 aa | 5 | NR | 0.86 |
| DH2 gene usage | | | | | |
| 22 | 22 | NR | 0.70 |
| JH6 gene usage | | | | | |
| 21 | 21 | NR | 0.86 |
| Del (11q) and/or del(17p) | | | | | |
| 7 | 4.2 (2.8–5.6) | 0.04 |
| N. of cytogenetically altered CLL cells (×10^9/L) | | | | | |
| ≤33 | 57 | NR | |
| >33 | 18 | 7.4 (2.2–12.5) | 0.001 |

aa, amino acids; CI, confidence interval; HR, hazard ratio; N, number of cases; NR, not reached; y, years.
specific for a given epitope (39–41). Among other factors, this might also contribute to explain the more aggressive clinical course (42, 43) and the shortened survival of U-CLL vs. M-CLL (44). As a consequence, the IGHV gene mutational status currently represents one of the most relevant prognostic determinants in CLL (44).

Similarly to normal B-cells (31), here we show that CLL cells also display a Gaussian distribution according to the hydropathy index of their BCR, slightly skewed toward negatively charged HCDR3 amino acid sequences. Interestingly, when we divided our patients into cases with neutral (mean GS of -0.1) vs. more negatively charged (mean GS of -1.1) HCDR3 sequences, two subgroups of CLL patients with clearly distinct clinical and biological features emerged. Thus, CLL patients with neutral HCDR3 sequences showed a clear predominance of men, U-CLL with longer HCDR3 sequences, a lower frequency of IGHV gene mutation, and higher frequency of more advanced stages of the disease, in association with a higher rate of disease progression and shorter TTT. Interestingly, shortening of HCDR3 sequences with a trend to negatively charged BCRs is a typical feature of selection of B-cell precursors in BM required for the survival of B-cells that will enter the mature B-cell repertoire (31). Based on these findings, our results suggest that expanded CLL cells in patients with neutral and longer HCDR3 sequences might reflect an earlier tumor cell origin in BM (45–47). Among other factors, this might also contribute to explain the greater frequency of more advanced stages of disease at diagnosis (48), together with an increased rate of disease progression vs. patients with negatively charged HCDR3 sequences. Nevertheless, these differences could be potentially due to the fact that CLL cases with neutral HCDR3 sequences included a higher fraction of U-CLL vs. M-CLL patients.

To investigate the potential independent value of both variables (the BCR mutational status and its hydropathy index), we separately studied the features of CLL patients with neutral vs. negatively charged HCDR3 sequences among U-CLL and M-CLL cases. Thus, U-CLL cases with a neutral and negatively charged HCDR3 showed similar clinical and biological features associated with a uniformly poorer outcome, in line with previous observations (49–51). In contrast, the HCDR3 hydropathy index identified two different prognostic subgroups of M-CLL. These included a subgroup of M-CLL with neutral HCDR3 who displayed intermediate clinical, genetic, and biological features associated with a uniformly poorer outcome.
neutral HCDR3 showed predominance of men—similar to that found in U-CLL, but with significantly higher hemoglobin levels—in association with a higher frequency of thrombocytopenia and an intermediate frequency of cytogenetically altered cases between U-CLL and the other M-CLL patients, at the expense of a greater frequency of del(17p). At present, it is well established that progression of MBL toward CLL is associated with a more prominent male predominance and greater frequency of U-CLL (52). Male predominance among M-CLL cases with neutral HCDR3 might also contribute to explain the greater hemoglobin levels observed in these patients, which contrasts with the higher frequency of thrombocytopenia compared to M-CLL with negatively charged HCDR3 sequences. This together with the greater frequency of more advanced stage of the disease among M-CLL with a neutral vs. negatively charged HCDR3 would support a poorer outcome within M-CLL for the former patient group, as confirmed here via an adverse impact on the time elapsed from diagnosis to first therapy among M-CLL patients with neutral vs. negatively charged HCDR3 sequences.

From the molecular point of view, M-CLL with neutral HCDR3 showed DJ footprints compatible with a more immature BCR repertoire associated with preferential usage of D(H)2 IGHV gene segments (53), in the absence of a biased use of JH4 gene segments, as found in M-CLL cases with negatively charged HCDR3 sequences, being biased use of JH4 gene segments a typical feature of more mature PB B lymphocytes (54). In addition, we also observed longer HCDR3 sequences in older (≥65 y) patients who had U-CLL and M-CLL with neutral HCDR3 vs. M-CLL with negatively charged HCDR3 sequences, in line with what might be expected among older subjects (27). Despite U-CLL and M-CLL with neutral HCDR3 shared HCDR3 sequences which typically had no traits associated with a mature B-cell repertoire, important differences were still observed in the IGHV repertoire of CLL cells of both patient groups as regards the usage of the VH1 and VH3 gene segments, further emphasizing also the biological differences between them.

Altogether, our findings show that based on the HCDR3 hydropathy index of HCDR3 sequences, two clearly distinct subgroups of M-CLL patients with different clinical, genetic, and prognostic features can be identified which are characterized by neutral vs. negatively charged BCRs, associated with molecular features of precursor vs. peripheral/mature B-cells, respectively. Further studies are needed to elucidate the precise mechanisms involved in determining the role of these different BCR profiles (compared to other prognostic factors such as ZAP70) in the distinct clinical behavior and outcome of both groups of M-CLL patients and facilitate implementation of assays for routine assessment of the HCDR3 hydropathy index in M-CLL in the clinical settings.

**ETHICS STATEMENT**

The studies involving human participants were reviewed and approved by the local Institutional Ethics Committee, University Hospital of Salamanca (code of approval: CEIC-PI4705/2017). The patients/participants provided their written informed consent to participate in this study.

**AUTHOR CONTRIBUTIONS**

AR-C, JA, and AO contributed to conception and design of the study. BF, GO, IC, and MA organized the database. CP contributed to bioinformatics calculations. MP and AG-M contributed to genomic collection, storage, and quality control. AG-M performed part of the statistical analysis and critical review of manuscript. MGD, FF and AS-R contributed in the clinical part of the manuscript and critical review of manuscript. AR-C wrote the first draft of the manuscript. All authors contributed to the manuscript revision and read and approved the submitted version.

**FUNDING**

This work was supported by the following grants: FS/37-2017, from the Fundación Memoria D. Samuel Solórzano, Universidad de Salamanca; FIS PI17/00399-FEDER, from the Fondo de Investigación Sanitaria of Instituto de Salud Carlos III, Madrid, Spain; 0639_IDIAL_NET_3_E from cooperative network EP-INTERREG V A España Portugal (POCTEP); and ECRIN-M3, Accelerator Award Full, Cancer Research UK, Fundación Científica de la Asociación Española Contra el Cáncer (AECC), Fondazione AIRC per la Ricerca sul Cancro. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript.

**ACKNOWLEDGMENTS**

The authors would like to thank all the staff of the Cytometry and Cell Purification Services of the University of Salamanca; the hematologists Almudena Navarro, Monica Baile, and Jose M. Bastida (University Hospital of Salamanca); the Spanish National DNA Bank Carlos III (Banco Nacional de DNA Carlos III, University of Salamanca: www.bancoadn.org); and the Genomic Unit of Cancer Research Centre (IBMCC, USAL-CSIC) for their support in the data collection for the preparation of this manuscript.

**DATA AVAILABILITY STATEMENT**

The original contributions presented in the study are included in the article/Supplementary Material. Further inquiries can be directed to the corresponding authors.

**SUPPLEMENTARY MATERIAL**

The Supplementary Material for this article can be found online at: https://www.frontiersin.org/articles/10.3389/fonc.2021.723722/full#supplementary-material
Supplementary Figure 1 | Kyte-Doolittle numerical scale of aminoacids (aa) and the formula to calculate the Gravy Score (GS) of HCDR3 (hydrophy index). The biochemical nature of aa according to their Kyte-Doolittle value and the algorithm used to calculate the GS of the HCDR3 sequence in our patients are shown in (A, B), respectively. In (C), four different HCDR3 sequences with their corresponding GS (where the sum of the Kyte-Doolittle values for individual aa divided by HCDR3 length provides the specific GS of individual sequences). As shown, different patients can share the same GS of their HCDR3, despite having different aa sequences.

REFERENCES

1. Oppezzo P, Dighiero G. Role of the B-Cell Receptor and the Microenvironment in Chronic Lymphocytic Leukemia. Blood Cancer J (2013) 3:149. doi: 10.1038/bcj.2013.45
2. Hallek M. Chronic Lymphocytic Leukemia: 2020 Update on Diagnosis, Risk Stratification and Treatment. Am J Hematol (2019) 94(11):1266–87. doi: 10.1002/ajh.25595
3. Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F, Dighiero G, Döhner H, et al. iwCLL Guidelines for Diagnosis, Indications for Treatment, Response Assessment, and Supportive Management of CLL. Blood (2018) 131(25):2745–60. doi: 10.1182/blood-2017-09-806398
4. Dighiero G, Hamblin TJ. Chronic Lymphocytic Leukemia. Lancet (2008) 371(9617):1017–29. doi: 10.1016/S0140-6736(08)60456-0
5. International CLL-IPI working group. An International Prognostic Index for Patients With Chronic Lymphocytic Leukemia (CLL-IPI): A Meta-Analysis of Individual Patient Data. Lancet Oncol (2016) 17(6):779–90. doi: 10.1016/S1470-2045(16)30029-8
6. Puente XS, Beá S, Valdés-Mas R, Villamor N, Gutiérrez-Abril J, Martin-Subero JJ, et al. Non-Coding Recurrent Mutations in Chronic Lymphocytic Leukemia. Nature (2015) 526(7574):519–24. doi: 10.1038/nature16666
7. D’Avola A, Drennan S, Tracy I, Henderson I, Chioccio L, Larrayoz M, et al. Surface IgM Expression and Function are Associated With Clinical Behavior, Genetic Abnormalities, and DNA Methylation in CLL. Blood (2016) 128(6):816–26. doi: 10.1182/blood-2016-03-707786
8. Vardi A, Agathangelidis A, Sutton LA, Ghia P, Rosenquist R, Stamatopoulos K. Immunogenetic Studies of Chronic Lymphocytic Leukemia: Revelations and Speculations About Ontogeny and Clinical Evolution. Cancer Res (2014) 74(16):4211–6. doi: 10.1158/0008-5472.CAN-14-0630
9. Chiorazzi N, Stevenson FK. Celebrating 20 Years of IGHV Mutation Analysis in Chronic Lymphocytic Leukemia Cells Express Restricted Sets of Mutated and Unmutated Antigen Receptors. J Clin Invest (1998) 102:1515–25. doi: 10.1172/JCI3009
10. Dighiero G, Oppezzo P. What do Somatic Hypermutation and Class Switch Recombination Teach Us About Chronic Lymphocytic Leukemia Pathogenesis? Curr Top Microbiol Immunol (2005) 294:71–89. doi: 10.1007/3-540-29933-5_5
11. Ivanov I, Link J, Ippolito GC, Schroeder HW Jr. “Constraints on Hydrophathy and Sequence Composition of HCDR3 are Conserved Across Evolution”. In: M. Zanetti, editor. The Antibodies. London: Taylor and Francis (2002). p. 43–67.
12. Ivanov II, Schelonka RL, Zhaung Y, Garland GL, Zemlin M, Schroeder HW Jr. Development of the Expressed Ig CDR-H3 Repertoire is Marked by Focusing of Constraints in Length, Amino Acid Use, and Charge That Are First Established in Early B Cell Progenitors. J Immunol (2005) 174(12):7773–80. doi: 10.4049/jimmunol.174.12.7773
13. Faisi G, Ghiotto F, Hashimoto S, Sellers B, Valetto A, Allen SL, et al. Chronic Lymphocytic Leukemia B Cells Express Restricted Sets of Mutated and Unmutated Antigen Receptors. Haematologica (2014) 99(5):897–907. doi: 10.3324/haematol.2013.089913
14. Criado I, Muñoz-Criado S, Rodríguez-Caballero A, Nieto WG, Romero A, Fernández-Navarro P, et al. Host Virus and Pneumococcus-Specific Immune Responses in High Count Monoclonal B-Cell Lymphocytosis and Chronic Lymphocytic Leukemia: Implications for Disease Progression. Haematologica (2017) 102(7):1238–46. doi: 10.3324/haematol.2016.159012
15. Kyte J, Doolittle RF. A Simple Method for Displaying the Hydrophobic Character of a Protein. J Mol Biol (1982) 157(1):105–32. doi: 10.1016/0022-2836(82)90515-0
16. Criado I, Rodríguez-Caballero A, Gutiérrez ML, Pedreira CE, Alcocea M, Nieto W, et al. Low-Count Monoclonal B-Cell Lymphocytosis Persists After Seven Years of Follow Up and is Associated With a Poorer Outcome. Haematologica (2018) 103(7):1198–208. doi: 10.3324/haematol.2017.183954
17. Pickman Y, Dunn-Walters D, Mehr R. BCR CDR3 Length Distributions can be Used to Detect Myelodysplastic Syndrome. Phys Biol (2013) 10(5):56001. doi: 10.1088/1478-3975/10/5/056001
18. Kwak K, Akkaya M, Pierce SK. B Cell Signaling in Context. J Exp Med (2019) 208(9):963–9. doi: 10.1084/jem.2019014927
19. DeKosky BJ, Lungu OL, Park D, Johnson EL, Charab W, Chrysostomou C, et al. Large-Scale Sequence and Structural Comparisons of Human Naïve and Antigen-Independent Antibody Repertoires. Proc Nat Acad Sci USA (2016) 113(19):E2636–45. doi: 10.1073/pnas.1525510113
20. Khass M, Vale AM, Burrows PD, Schroeder HW Jr. The Sequences Encoded by Immunoglobulin Diversity (DH) Gene Segments Play Key Roles in Controlling B-Cell Development, Antigen-Binding Site Diversity, and Antibody Production. Immunol Rev (2018) 284(1):106–19. doi: 10.1111/imr.12669
21. Kaplinsky J, Li A, Sun A, Coffre M, Koralov SB, Arnaout R. Antibody Repertoire Deep Sequencing Reveals Antigen-Independent Selection in Maturing B Cells. Proc Natl Acad Sci USA (2014) 111(25):E2622–9. doi: 10.1073/pnas.1403278111
22. Haselager MV, Kater AP, Eldering E. Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing? Front Oncol (2020) 10:592205. doi: 10.3389/fonc.2020.592205
23. Greaves M. Clonal Expansion in B-CLL: Fungal Drivers or Self-Service? J Exp Med (2013) 210(1):1–3. doi: 10.1084/jem.20122739
47. Rodríguez-Caballero et al. HCDR3 Hydropathy Index in CLL